Jiade Jay Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jiade Jay Lu has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Ivan Weng Keong Tham
Department of Radiation Oncology, National University Cancer Institute, Singapore
4 shared publications - Jianji Pan
Fujian Medical University
4 shared publications - Amarjit Kaur
Nanyang Polytechnic, School of Health Sciences, 180 Ang Mo Kio Avenue 8 Singapore 569830
2 shared publications - Khai Mun Lee
National University Cancer Institute, Department of Radiation Oncology, National University of Singapore, 1E Kent Ridge Road, Tower Block, Level 7, Singapore 119 228
2 shared publications Lu Han
Department of Radiation Oncology, Cancer Hospital of Fujian Medical University, Fuzhou, Fujian, China
2 shared publicationsLuther W. Brady
Hylda Cohn/American Cancer Society, Clinical Oncology, College of Medicine, Drexel University, Philadelphia, USA
2 shared publications
Latest Publications
- 1 March 2014
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 110 (3) , 385-389
Update report of nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy and hypothesis of the optimal margin
- 1 March 2014
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 110 (3) , 385-389
Update report of nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy and hypothesis of the optimal margin
- Open Access
- 1 November 2013
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. 6, 1701-6
Body mass index and patient CT measurements as a predictor of benefit of intensity-modulated radiotherapy to the supraclavicular fossa
Peer reviewed article authored by (Koh V, Tang JI, Choo BA, Tan CW, Lim BK, Shen L, Lu JJ). Read article or submit your manuscript for publishing.
- 1 November 2013
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. 6, 1701-6
Open AccessBody mass index and patient CT measurements as a predictor of benefit of intensity-modulated radiotherapy to the supraclavicular fossa
Peer reviewed article authored by (Koh V, Tang JI, Choo BA, Tan CW, Lim BK, Shen L, Lu JJ). Read article or submit your manuscript for publishing.
- 3 September 2013
- Published by Springer Nature in Journal of Radiation Oncology
- Vol. 2 (3) , 231
Statement on research and publication ethics
- 3 September 2013
- Published by Springer Nature in Journal of Radiation Oncology
- Vol. 2 (3) , 231
Statement on research and publication ethics
- 1 October 2012
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 35 (5) , 474-479
Combined High-dose Radiation Therapy and Systemic Chemotherapy Improves Survival in Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer
Objectives To investigate the efficacy of high-dose radiation therapy (RT) to the primary and regional disease in combination with systemic chemotherapy and local treatment to metastatic foci in patients with newly diagnosed metastatic nasopharyngeal carcinoma (NPC). Methods One hundred and five consecutive patients with pathologically confirmed NPC with distant metastasis at diagnosis seen between 1995 and 2002 were reviewed. All were offered cisplatin-based chemotherapy, high-dose RT (>30 Gy) to the head and neck region, and active treatment to the metastatic foci. Results Patients’ median age was 46 years, and all had a Karnofsky Performance Score of ≥70. Eighty-nine patients (85%) had metastases confined to 1 organ. Ninety-six patients (91%) received at least 1 cycle of chemotherapy and 71 (68%) received greater than 65 Gy of radiation to the head and neck region. With a median follow-up time of 22 months (range: 2 to 142 mo), 90 patients had deceased, and the median survival time of the entire group was 25 months. The 2 and 5-year estimated overall survival rates were 50% and 17%, respectively. Radiation dose of greater than 65 Gy to the primary region (P = 0.05) and number of organs with metastases (single vs. multiple) (P = 0.002) were independent predictive factors for overall survival on log-rank tests. Only moderately severe acute toxicities, such as Radiation Therapy Oncology Group grade 3 mucositis, skin desquamation, and leukocytopenia were observed. No patient experienced grade 4 acute toxicities. Conclusions High-dose RT is indicated for local disease control in patients with metastatic NPC, and may improve survival when actively used with systemic chemotherapy and local treatment for metastatic foci. Patients with single-organ metastases have a better prognosis as compared with those with more widespread metastases.
- 1 October 2012
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 35 (5) , 474-479
Combined High-dose Radiation Therapy and Systemic Chemotherapy Improves Survival in Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer
Objectives To investigate the efficacy of high-dose radiation therapy (RT) to the primary and regional disease in combination with systemic chemotherapy and local treatment to metastatic foci in patients with newly diagnosed metastatic nasopharyngeal carcinoma (NPC). Methods One hundred and five consecutive patients with pathologically confirmed NPC with distant metastasis at diagnosis seen between 1995 and 2002 were reviewed. All were offered cisplatin-based chemotherapy, high-dose RT (>30 Gy) to the head and neck region, and active treatment to the metastatic foci. Results Patients’ median age was 46 years, and all had a Karnofsky Performance Score of ≥70. Eighty-nine patients (85%) had metastases confined to 1 organ. Ninety-six patients (91%) received at least 1 cycle of chemotherapy and 71 (68%) received greater than 65 Gy of radiation to the head and neck region. With a median follow-up time of 22 months (range: 2 to 142 mo), 90 patients had deceased, and the median survival time of the entire group was 25 months. The 2 and 5-year estimated overall survival rates were 50% and 17%, respectively. Radiation dose of greater than 65 Gy to the primary region (P = 0.05) and number of organs with metastases (single vs. multiple) (P = 0.002) were independent predictive factors for overall survival on log-rank tests. Only moderately severe acute toxicities, such as Radiation Therapy Oncology Group grade 3 mucositis, skin desquamation, and leukocytopenia were observed. No patient experienced grade 4 acute toxicities. Conclusions High-dose RT is indicated for local disease control in patients with metastatic NPC, and may improve survival when actively used with systemic chemotherapy and local treatment for metastatic foci. Patients with single-organ metastases have a better prognosis as compared with those with more widespread metastases.
- 13 September 2012
- Published by Wiley in Head & Neck
- Vol. 35 (9) , 1238-1247
Prognostic significance of expression of cyclooxygenase‐2, vascular endothelial growth factor, and epidermal growth factor receptor in nasopharyngeal carcinoma
Background: The association between expression of cyclooxygenase‐2 (COX‐2), vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), and the long‐term outcomes in treated nasopharyngeal carcinoma (NPC) was studied.Methods: Expression of COX‐2, VEGF, and EGFR by immunohistochemical (IHC) staining was assessed in 128 patients with NPC. Overall survival (OS), disease‐free survival (DFS), locoregional control, and distant metastasis‐free survival rates were compared for different expression levels of each marker. Multivariate analysis was by the Cox regression model.Results: Median follow‐up after radiation therapy ± chemotherapy was 116 months. Univariate and multivariate analyses demonstrated that COX‐2, VEGF, EGFR, and clinical stage were all independent predictors for OS, DFS, locoregional control, and distant metastasis–free survival rates.Conclusions: High expression of COX‐2, VEGF, and EGFR were independent adverse prognostic factors for long‐term outcomes in nonmetastatic NPC independent of clinical stage. © 2012 Wiley Periodicals, Inc. Head Neck, 2013
- 13 September 2012
- Published by Wiley in Head & Neck
- Vol. 35 (9) , 1238-1247
Prognostic significance of expression of cyclooxygenase‐2, vascular endothelial growth factor, and epidermal growth factor receptor in nasopharyngeal carcinoma
Background: The association between expression of cyclooxygenase‐2 (COX‐2), vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), and the long‐term outcomes in treated nasopharyngeal carcinoma (NPC) was studied.Methods: Expression of COX‐2, VEGF, and EGFR by immunohistochemical (IHC) staining was assessed in 128 patients with NPC. Overall survival (OS), disease‐free survival (DFS), locoregional control, and distant metastasis‐free survival rates were compared for different expression levels of each marker. Multivariate analysis was by the Cox regression model.Results: Median follow‐up after radiation therapy ± chemotherapy was 116 months. Univariate and multivariate analyses demonstrated that COX‐2, VEGF, EGFR, and clinical stage were all independent predictors for OS, DFS, locoregional control, and distant metastasis–free survival rates.Conclusions: High expression of COX‐2, VEGF, and EGFR were independent adverse prognostic factors for long‐term outcomes in nonmetastatic NPC independent of clinical stage. © 2012 Wiley Periodicals, Inc. Head Neck, 2013
- 4 August 2012
- Published by Springer Nature
- p. 239-245
Palliative Radiation for Brain Metastases
- Open Access
- 21 March 2012
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 1-13
Patterns of regional lymph node metastasis of nasopharyngeal carcinoma: A meta-analysis of clinical evidence
- 21 March 2012
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 1-13
Open AccessPatterns of regional lymph node metastasis of nasopharyngeal carcinoma: A meta-analysis of clinical evidence
- 17 March 2012
- Published by Springer Nature in Journal of Radiation Oncology
- Vol. 1 (1) , 1
From the editorial board
- 17 March 2012
- Published by Springer Nature in Journal of Radiation Oncology
- Vol. 1 (1) , 1
From the editorial board
- 9 November 2011
- Published by Wiley
- No. 11
Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases
- 9 November 2011
- Published by Wiley
- No. 11
Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases
- Open Access
- 18 February 2011
- Published by Springer Nature in Radiation Oncology
- Vol. 6 (1) , 18
Erratum To: An ultrasonographic evaluation of skin thickness in breast cancer patients after postmastectomy radiation therapy
- 18 February 2011
- Published by Springer Nature in Radiation Oncology
- Vol. 6 (1) , 18
Open AccessErratum To: An ultrasonographic evaluation of skin thickness in breast cancer patients after postmastectomy radiation therapy